US Patent 10,583,121: Asenapine Transdermal Patch Claims, Expiration, Orange Book Status, and Generic Risk
US Patent 10,583,121 protects a specific asenapine transdermal patch architecture and a defined pharmacokinetic performance profile. The core combination is a styrene-isoprene-styrene adhesive, sodium diacetate, isopropyl palmitate, and asenapine, preferably asenapine maleate. The independent claims also require a normalized 24-hour exposure threshold and suppression of an asenapine metabolite.
The patent is materially narrower than a generic claim to any asenapine patch. A competing product would need to avoid at least one required structural component, numerical formulation range, or pharmacokinetic limitation to reduce literal infringement risk. Because the claims include measurable composition and exposure limitations, invalidity and non-infringement disputes would likely focus on enablement, written description, claim construction, formulation testing, and pharmacokinetic reproducibility.
What does US Patent 10,583,121 protect?
US Patent 10,583,121 protects an asenapine patch having both a defined formulation and a defined systemic exposure profile.
| Required element |
Scope of requirement |
| Dosage form |
Patch for transdermal administration |
| Physical structure |
Support layer plus adhesive agent layer |
| Adhesive base |
10% to 90% by mass of the adhesive layer |
| Required polymer |
Styrene-isoprene-styrene block copolymer |
| Required additive |
Sodium diacetate |
| Required permeation enhancer |
Isopropyl palmitate |
| Active ingredient |
Asenapine or pharmaceutically acceptable salt |
| Dose normalization |
3.4 mg of free asenapine |
| Exposure requirement |
AUC2-120 of free asenapine of at least 27,000 pg·hr/mL |
| Metabolite requirement |
Metabolite AUC2-120 no more than 20% of free-asenapine AUC2-120 |
The patent does not cover every asenapine transdermal delivery system. Its central limitation is the combination of adhesive chemistry and pharmacokinetic performance.
The claims cover products that satisfy the listed components even if the product has additional ingredients, provided the additional ingredients do not remove or alter a required element. A patch with a different adhesive polymer, no sodium diacetate, or no isopropyl palmitate would present a stronger literal non-infringement position.
How broad is independent claim 1?
Claim 1 is a composition-and-performance claim. It requires:
- A support layer.
- An adhesive layer on the support.
- An adhesive base agent containing styrene-isoprene-styrene block copolymer.
- Adhesive base agent content of 10% to 90% by mass.
- Sodium diacetate.
- Isopropyl palmitate.
- Asenapine or a pharmaceutically acceptable salt.
- A normalized asenapine dose of 3.4 mg for the pharmacokinetic limitation.
- Free-asenapine AUC2-120 of at least 27,000 pg·hr/mL.
- Metabolite AUC2-120 of no more than 20% of the free-asenapine AUC2-120.
The claim is structurally narrower than a conventional Markush claim covering any adhesive, enhancer, or salt. It is functionally broader in one respect because it does not require a specific commercial patch size, total drug loading, release rate, backing material, or named metabolite in the text supplied.
What formulation components are protected?
The required formulation components are cumulative:
- Styrene-isoprene-styrene block copolymer
- Sodium diacetate
- Isopropyl palmitate
- Asenapine or its pharmaceutically acceptable salt
The claim does not require a tackifier or softener. Those ingredients appear only in dependent claims 6 through 9 and the corresponding method claims.
The 10% to 90% adhesive-base range is broad. It leaves substantial formulation latitude for the proportions of drug, sodium diacetate, isopropyl palmitate, tackifier, softener, and other excipients. The formulation still must produce the claimed pharmacokinetic result.
What do claims 2 through 10 add?
Claims 2 through 10 narrow the patch claim through composition and ratio limitations.
| Claim |
Added limitation |
| 2 |
Asenapine-to-sodium-diacetate mole ratio of 1:0.5 to 1:4 |
| 3 |
Pharmaceutically acceptable salt is asenapine maleate |
| 4 |
Asenapine content, calculated as free asenapine, is 1% to 15% by mass |
| 5 |
Free-asenapine-to-isopropyl-palmitate mass ratio is 1:0.1 to 1:10 |
| 6 |
Adhesive layer includes a tackifier |
| 7 |
Adhesive-base-to-tackifier mass ratio is 1:6 to 1.5:1 |
| 8 |
Adhesive layer includes a softener |
| 9 |
Adhesive-base-to-softener mass ratio is 1:6 to 5:1 |
| 10 |
Combines the claim 2 mole ratio and claim 4 drug-content range |
The most commercially relevant dependent claims are claims 3, 4, 5, and 10. Asenapine maleate is the principal pharmaceutical form used in the marketed product lineage. Claims 4 and 10 impose formulation windows that could capture practical commercial formulations while narrowing the claim against design-around products.
What do claims 11 through 20 protect?
Claims 11 through 20 are method-of-treatment claims. They recite treatment of a central nervous system disease by applying the claimed patch to a patient's skin.
The method claims largely repeat the product limitations. They do not create a broad method claim covering oral or sublingual asenapine. They require use of a patch having the same adhesive composition and pharmacokinetic profile as claim 1.
Potentially relevant diseases include conditions for which asenapine is used as an antipsychotic, particularly schizophrenia and bipolar I disorder. The supplied claim language uses the broader expression "central nervous system disease." That wording may create scope and enablement issues if the specification does not support treatment across the full breadth of central nervous system disorders.
What is the significance of the method-of-use claims?
The method claims can create infringement exposure for:
- A manufacturer that induces use of an infringing patch.
- A distributor that markets the patch for the claimed treatment.
- A healthcare provider or patient using the product, although enforcement is ordinarily directed at commercial actors.
- An ANDA applicant whose labeling instructs use for the claimed disease.
The method claims may remain relevant after a formulation claim is challenged, but their enforceability depends on the same composition and pharmacokinetic limitations. A noninfringing patch formulation would generally avoid both the product claims and the corresponding method claims.
When does US Patent 10,583,121 expire?
The patent has a 20-year term measured from the relevant nonprovisional or international filing date, subject to any patent-term adjustment. The published patent record identifies a 2016 priority framework for the asenapine patch technology. The expected nominal expiration is in 2036, with the exact effective expiration dependent on the patent's term-adjustment calculation and any terminal disclaimer.
| Event |
Date or period |
| Priority development |
2015-era Japanese priority filings |
| International/PCT filing framework |
2016 |
| US patent grant |
March 10, 2020 |
| Nominal patent term |
Approximately 2036 |
| Patent-term adjustment |
Must be confirmed from the USPTO patent-term calculation |
| FDA product approval for Secuado |
October 11, 2019 |
Patent expiration should not be treated as identical to FDA exclusivity expiration. FDA marketing exclusivity for a new dosage form can expire years before the listed patent.
What is the FDA and Orange Book status of the asenapine patch?
The FDA approved Secuado, an asenapine transdermal system, on October 11, 2019, for the treatment of adults with schizophrenia. Secuado is a transdermal formulation of asenapine and was developed by Noven Pharmaceuticals, a company within the Hisamitsu group.
| Regulatory item |
Status |
| Product |
Secuado |
| Active ingredient |
Asenapine |
| Dosage form |
Transdermal system |
| Applicant |
Noven Pharmaceuticals, Inc. |
| FDA approval |
October 11, 2019 |
| Initial indication |
Schizophrenia in adults |
| Regulatory pathway |
NDA |
| New chemical entity exclusivity |
No, asenapine was previously approved as Saphris |
| New clinical investigation exclusivity |
Generally three years for the new dosage form, subject to FDA Orange Book coding |
| Orange Book patent relevance |
Product-specific patent listings control ANDA certification obligations |
The FDA initially approved asenapine sublingual tablets under the brand Saphris in 2009. Secuado therefore did not receive five-year new chemical entity exclusivity. Its principal regulatory protection came from the new dosage form, clinical data, and patent estate.
An ANDA applicant challenging a listed patent may submit a Paragraph IV certification. If the NDA holder brings suit within 45 days, FDA approval can be stayed for up to 30 months, subject to statutory exceptions and later court developments.
How strong is the patent estate for Secuado?
The estate is strongest against a transdermal product that replicates the commercial formulation architecture. It is weaker against a materially different patch platform.
Strengths
- The claims require several specific formulation ingredients.
- The pharmacokinetic limitation links the formulation to a measurable therapeutic exposure.
- Claims cover both the patch and treatment using the patch.
- Dependent claims provide narrower fallback positions for asenapine maleate and quantitative formulation ranges.
- The patent term extends well beyond the product's three-year regulatory exclusivity period.
Vulnerabilities
- The AUC limitation may require detailed testing and raise questions about assay methodology and subject variability.
- The claim refers to an "asenapine metabolite" without the supplied language identifying a single metabolite. Claim construction may be disputed.
- The phrase "when ... the content ... is 3.4 mg" creates a normalization issue for products with different drug loading.
- A competitor may use a different pressure-sensitive adhesive system.
- A competitor may replace sodium diacetate or isopropyl palmitate while preserving transdermal delivery.
- The broad "central nervous system disease" language may face written-description or enablement scrutiny depending on the specification.
The patent is therefore more effective as a formulation-specific barrier than as a platform patent covering all asenapine patches.
What generic entry risks exist?
A conventional generic tablet does not directly practice the transdermal patch claims. A generic or follow-on product would need to be a transdermal asenapine system to face the principal claim set.
Likely entry scenarios
| Entry scenario |
Patent risk |
| Generic sublingual asenapine tablet |
Limited exposure to this patent |
| Transdermal patch using the same four required ingredients |
High literal infringement risk |
| Patch using asenapine maleate and claimed ratios |
Higher risk |
| Patch using a different adhesive polymer |
Reduced literal infringement risk |
| Patch without sodium diacetate |
Reduced literal infringement risk |
| Patch without isopropyl palmitate |
Reduced literal infringement risk |
| Patch with materially different exposure profile |
Possible non-infringement, subject to testing |
| Non-ANDA branded transdermal product |
Patent and regulatory litigation risk remains |
A Paragraph IV challenge would likely attack the patent on obviousness, lack of written description, enablement, indefiniteness, or failure to satisfy the claimed pharmacokinetic relationship. The challenger could also argue that the claimed excipient combination and transdermal delivery objective were predictable from prior art involving asenapine, pressure-sensitive adhesives, permeation enhancers, and acidifying agents.
Which companies are positioned in the asenapine market?
| Company |
Product or role |
Relevance |
| Noven Pharmaceuticals |
Secuado developer and NDA applicant |
Commercial transdermal product |
| Hisamitsu Pharmaceutical |
Parent/group company associated with Noven |
Patent and commercial ownership context |
| Organon and prior Schering-Plough entities |
Saphris commercialization history |
Sublingual asenapine market |
| Generic manufacturers |
Potential ANDA applicants |
Primarily relevant to oral asenapine unless developing patches |
The principal competitive distinction is between oral or sublingual asenapine and transdermal asenapine. An oral generic does not substitute for Secuado in every regulatory or clinical context because dosage form, administration, adherence, and pharmacokinetic profiles differ.
Does biosimilar risk apply to asenapine?
No. Asenapine is a small-molecule active pharmaceutical ingredient, not a biologic. Biosimilar approval under the Public Health Service Act is not the applicable pathway.
Competitive entry would proceed through an ANDA for a pharmaceutically equivalent product or through a separate NDA for a materially different transdermal product. The primary legal mechanisms are Paragraph IV certification, patent litigation, Hatch-Waxman stays, and possible settlement agreements.
What litigation and settlement issues affect the patent?
The key litigation trigger would be an ANDA or competing NDA for an asenapine transdermal system that references Secuado or relies on its formulation and clinical data.
The relevant dispute points would include:
- Whether the accused adhesive contains a styrene-isoprene-styrene block copolymer.
- Whether the adhesive-base content falls within 10% to 90%.
- Whether sodium diacetate and isopropyl palmitate are present.
- Whether the drug content falls within the claimed ranges.
- Whether the accused product satisfies the AUC2-120 limits.
- Whether the metabolite limitation is definite and reproducible.
- Whether the asserted claims are obvious in view of prior transdermal asenapine formulations.
- Whether the method claims are induced by the proposed labeling.
No settlement terms should be inferred merely from a Paragraph IV filing. Hatch-Waxman cases can end through license agreements, delayed-entry settlements, consent judgments, or claim narrowing. A settlement could grant an authorized generic license or establish a date earlier than patent expiration, but the supplied record does not establish such an agreement.
How does US Patent 10,583,121 compare with the oral asenapine estate?
| Issue |
Transdermal asenapine |
Oral or sublingual asenapine |
| Representative product |
Secuado |
Saphris |
| Administration |
Skin patch |
Sublingual tablet |
| Main patent focus |
Adhesive composition and exposure profile |
Active ingredient, formulation, method of treatment |
| Key regulatory product |
2019 NDA |
2009 NDA |
| Biosimilar pathway |
Not applicable |
Not applicable |
| Generic substitution |
Requires transdermal equivalent |
Oral generic pathway |
| Main commercial barrier |
Patch formulation and patent estate |
Earlier oral product patents and regulatory exclusivity |
The patent at issue is not a basic asenapine composition-of-matter patent. Its commercial value depends on the transdermal delivery system, product differentiation, and the ability to enforce formulation and pharmacokinetic limitations.
Key Takeaways
- US Patent 10,583,121 covers a specific asenapine patch, not every asenapine transdermal product.
- The required formulation includes styrene-isoprene-styrene, sodium diacetate, isopropyl palmitate, and asenapine or its salt.
- The claims require free-asenapine AUC2-120 of at least 27,000 pg·hr/mL and metabolite exposure of no more than 20% of the asenapine exposure.
- Claims 11 through 20 extend the same limitations to treatment methods for central nervous system disease.
- The patent has an expected term into approximately 2036, subject to USPTO patent-term adjustment.
- Secuado received FDA approval in 2019 as a transdermal asenapine product for schizophrenia.
- Three-year new clinical investigation exclusivity is separate from the patent term and does not create five-year NCE protection.
- Generic oral asenapine does not directly practice the transdermal claims.
- A competing transdermal patch would face the highest risk if it uses the same adhesive polymer, sodium diacetate, isopropyl palmitate, and exposure profile.
- The strongest design-around options involve a different adhesive system, omission of a required excipient, or a materially different pharmacokinetic profile.
FAQs About US Patent 10,583,121
Is US Patent 10,583,121 a composition-of-matter patent?
No. It is directed to a transdermal patch formulation and related treatment methods. It does not claim asenapine as a new chemical entity.
Does the patent cover any patch containing asenapine maleate?
No. The patch must satisfy the independent structural and pharmacokinetic limitations. Asenapine maleate is expressly recited in dependent claims, but the salt alone does not establish infringement.
Can a generic company launch an oral asenapine product before 2036?
Potentially, subject to separate patents, FDA requirements, and any Orange Book-listed patents covering the oral product. US Patent 10,583,121 principally concerns transdermal delivery.
What test would be needed to evaluate infringement?
The product would require formulation analysis, polymer identification, excipient quantification, drug-loading calculations, and pharmacokinetic testing using the claim's AUC2-120 and metabolite methodology.
Is Secuado protected by biosimilar exclusivity?
No. Secuado contains a small-molecule drug. Any competing product would use an ANDA or NDA pathway rather than the biosimilar pathway.
References
-
U.S. Food and Drug Administration. (2009). FDA approves Saphris (asenapine) for schizophrenia and bipolar disorder. FDA.
-
U.S. Food and Drug Administration. (2019). FDA approves new transdermal formulation of asenapine for schizophrenia. FDA.
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. Orange Book.
-
U.S. Patent and Trademark Office. (2020). U.S. Patent No. 10,583,121: Patch for administering asenapine. U.S. Department of Commerce.
-
Noven Pharmaceuticals, Inc. (2019). Secuado (asenapine) transdermal system prescribing information. U.S. Food and Drug Administration.